Abstract
BackgroundTofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA).ObjectivesTo assess the efficacy and safety of tofacitinib vs placebo (PBO) in patients (pts) with active...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have